Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with refractory metastatic colorectal cancer. Clinical data from patients diagnosed with colorectal cancer will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of medical oncology of the Department of Medicine, Queen Mary Hospital.
Colorectal Cancer
DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Irinotecan
Objective response rate, Change from baseline in size approximately every 8 weeks (4 cycles), up to approximately 12 months
Progression-free survival, From date of start until the date of first documented progression or death from disease-related causes or last follow-up, whichever came first, assessed up to 18 months|Overall survival, From date of start until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with refractory metastatic colorectal cancer. Clinical data from patients diagnosed with colorectal cancer will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of medical oncology of the Department of Medicine, Queen Mary Hospital.